StemCell Institute (TSE:7096) PE Ratio: 49.76 (As of Jul. 13, 2026) — 54% Below Median


TSE:7096 StemCell Institute TSE:7096
69 GF Score
Price 円768.00
GF Value 円1,813.29
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is StemCell Institute PE Ratio?

StemCell Institute TSE:7096 +0.92% 69 PE Ratio is 49.76 as of Jul. 13, 2026, which is 54% below its 10-year median of 107.58. GuruFocus rates TSE:7096 with a GF Score™ of 69/100 and a GF Value™ of 円1,813.29 (Possible Value Trap). The stock has 6 warning signs investors should review.

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-13), StemCell Institute's share price is 円768.00. StemCell Institute's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was 円15.43. Therefore, StemCell Institute's PE Ratio for today is 49.76.

Warning Sign:

StemCell Institute stock PE Ratio (=49.74) is close to 1-year high of 50.78.

During the past 9 years, StemCell Institute's highest PE Ratio was 534.57. The lowest was 20.28. And the median was 107.58.

StemCell Institute's EPS (Diluted) for the six months ended in Mar. 2026 was 円7.05. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was 円15.43.

As of today (2026-07-13), StemCell Institute's share price is 円768.00. StemCell Institute's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was 円15.41. Therefore, StemCell Institute's PE Ratio without NRI ratio for today is 49.83.

During the past 9 years, StemCell Institute's highest PE Ratio without NRI was 528.96. The lowest was 26.76. And the median was 99.92.

StemCell Institute's EPS without NRI for the six months ended in Mar. 2026 was 円7.06. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was 円15.41.

During the past 12 months, StemCell Institute's average EPS without NRI Growth Rate was -46.00% per year. During the past 3 years, the average EPS without NRI Growth Rate was -9.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was 22.10% per year.

During the past 9 years, StemCell Institute's highest 3-Year average EPS without NRI Growth Rate was 64.30% per year. The lowest was -9.50% per year. And the median was -1.80% per year.

StemCell Institute's EPS (Basic) for the six months ended in Mar. 2026 was 円7.06. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was 円15.44.

Back to Basics: PE Ratio


StemCell Institute  (TSE:7096) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


StemCell Institute PE Ratio Related Terms


StemCell Institute PE Ratio Historical Data

* Premium members only.

The historical data trend for StemCell Institute's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

StemCell Institute PE Ratio Chart

StemCell Institute Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
PE Ratio
Get a 7-Day Free Trial Premium Member Only 152.08 130.11 65.44 36.02 49.61

StemCell Institute Semi-Annual Data
Mar18 Mar19 Mar20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 65.44 113.32 36.02 At Loss 49.61

TSE:7096 vs VRTX, REGN, ALNY: PE Ratio Comparison

For the Biotechnology subindustry, StemCell Institute's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


StemCell Institute PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, StemCell Institute's PE Ratio distribution charts can be found below:

* The bar in red indicates where StemCell Institute's PE Ratio falls into.


TSE:7096
69GF Score
StemCell Institute TSE:7096
PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

StemCell Institute PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

StemCell Institute's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=768.00/15.433
=49.76

StemCell Institute's Share Price of today is 円768.00.
For company reported semi-annually, StemCell Institute's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円15.43.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio →
What does a PE Ratio of 49.76 mean?
StemCell Institute (TSE:7096) has a PE Ratio of 49.76 as of Jul. 13, 2026. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on StemCell Institute and its competitors. This is 54% below median its historical median of 107.58. Over the past decade, StemCell Institute's PE Ratio has ranged from 20.28 to 534.57.
Is StemCell Institute's PE Ratio too high?
StemCell Institute's current PE Ratio of 49.76 is 54% below median its 10-year median of 107.58. Over the past 10 years, this metric has ranged from a low of 20.28 to a high of 534.57. Overall, StemCell Institute has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does StemCell Institute's PE Ratio compare to VRTX and REGN?
StemCell Institute's PE Ratio of 49.76 can be compared against companies in the Biotechnology industry. Historically, StemCell Institute's own PE Ratio has ranged from 20.28 to 534.57 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio for a Biotechnology company?
A good PE Ratio depends on the Biotechnology industry context. However, PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio mean?
A high PE Ratio can signal that a stock is expensive relative to its fundamentals. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on StemCell Institute and its competitors. StemCell Institute's current PE Ratio is 49.76, which is 54% below median its own 10-year median of 107.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCell Institute stock overvalued right now?
Based on GuruFocus' analysis, StemCell Institute (TSE:7096) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,813.29, compared to a current price of 円768.00 — trading 57.6% below its estimated fair value. The current PE Ratio is 49.76, which is 54% below median its 10-year median of 107.58. StemCell Institute's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio calculated?
PE Ratio is calculated from a company's financial statements. For StemCell Institute (TSE:7096), the current PE Ratio is 49.76 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is StemCell Institute (TSE:7096) Overvalued in 2026?

Based on GuruFocus' analysis, StemCell Institute stock appears to be undervalued. The current stock price of 円768.00 is trading 57.6% below its estimated GF Value™ of 円1,813.29. GuruFocus considers StemCell Institute to be Possible Value Trap.

Key valuation signals for TSE:7096:

  • PE Ratio: 49.76 (54% below median its 10-year median of 107.58)
  • GF Value™: 円1,813.29 vs. price of 円768.00 (57.6% below fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the TSE:7096 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


StemCell Institute Business Description

Address 1-21-19 Toranomon, Minato-ku, Tokyo, JPN, 105-0001
StemCell Institute is engaged in the Cell bank business that separates and stores cord blood for regenerative medicine. Cord blood is the baby's blood contained in the umbilical cord and placenta that connects the mother and baby. In its umbilical cord blood storage business, upon receiving notification from customers who have contracted, umbilical cord blood collected at obstetric facilities throughout Japan is collected, transported to the company's cell processing center within 48 hours, and it provides a service to store cells at ultra-low temperature after separating cells from blood. The Company operates in a single segment, the cell bank business sales consist of three components: technical fees, storage fees, and other fees.
69GF Score

Get the complete analysis for TSE:7096

PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円768.00
Price
円1,813.29
GF Value